基于小鼠黑色素瘤肺转移模型探讨丙泊酚上调DR5表达发挥抑瘤作用的研究

周超瑞; 马伟斌; 叶孝乾; 陈娜; 李明娟

doi:10.16766/j.cnki.issn.1674-4152.002539

基于小鼠黑色素瘤肺转移模型探讨丙泊酚上调DR5表达发挥抑瘤作用的研究

doi: 10.16766/j.cnki.issn.1674-4152.002539

周超瑞^{1, 2},
马伟斌¹,
叶孝乾³,
陈娜¹,
李明娟^4, ,

1.
海警医院麻醉科，浙江嘉兴 314000
2.
浙江中医药大学研究生院，浙江杭州 310053
3.
海警医院病理科，浙江嘉兴 314000
4.
嘉兴学院医学院，浙江嘉兴 314001

基金项目:

浙江省基础公益研究项目 LGD21H300001

详细信息

通讯作者:
李明娟, E-mail: limingjuan@zjxu.edu.cn

中图分类号: R739.5 R73-3
计量
- 文章访问数: 187
- HTML全文浏览量: 118
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-18
- 网络出版日期: 2022-09-23

Study on the inhibitory effect of propofol on upregulation of DR5 expression based on mouse melanoma lung metastasis model

1.
Department of Anesthesiology, China Coast Guard Hospital of the People's Armed

摘要

摘要: 目的恶性黑色素瘤是一种恶性化程度高、易转移的由黑色素细胞恶性增殖引起的皮肤癌。本研究旨在探讨丙泊酚对小鼠B16F10黑色素瘤肺转移的抑制作用，以期为丙泊酚是否更适用于黑色素瘤相关手术麻醉提供一定的理论基础。方法体外细胞实验采用CCK-8方法考察不同浓度的丙泊酚对B16F10细胞增殖的抑制作用；流式细胞术检测不同实验组B16F10细胞凋亡率；Western blotting法检测各实验组DR5蛋白表达的变化。体内实验采用尾静脉注射B16F10细胞方法建立模型组，将C57BL/6J雄性小鼠24只, 采用随机数字表法分为4组, 即正常对照组, 黑色素瘤肺转移模型组, 丙泊酚50 mg/kg、10 mg/kg剂量组, 每组6只，观察腹腔注射丙泊酚对小鼠肺组织肿瘤转移结节的影响。结果体外实验结果显示，对照组与10 μmol/L、50 μmol/L、100 μmol/L 3个浓度实验组于72 h时的细胞相对增殖能力(490 nm OD值)分别为0.91±0.03、0.81±0.02、0.71±0.02和0.61±0.02；100 μmol/L丙泊酚处理B16F10细胞在24 h、48 h和72 h三个时间点的细胞凋亡率分别为(8.09±1.01)%、(26.04±1.10)%、(32.94±1.30)%，100 μmol/L丙泊酚处理B16F10细胞72 h，DR5蛋白表达显著上调。体内实验证实，50 mg/kg剂量的丙泊酚腹腔注射可以显著抑制肺转移黑色素瘤的结节数，且免疫组化结果显示，丙泊酚组肺组织中DR5的表达显著增加。结论丙泊酚能够抑制小鼠肺转移黑色素瘤，其机制可能与上调DR5蛋白表达相关。
- 恶性黑色素瘤 /
- 丙泊酚 /
- 死亡受体5 /
- 增殖 /
- 凋亡
Abstract: Objective Melanoma is a skin cancer caused by a malignancy of melanocytes. The incidence of melanoma is rapidly increasing worldwide, thus resulting in public health problems. Surgical resection is still the main method of early treatment. As a commonly used intravenous general anaesthesia drug, propofol has been reported to have a certain inhibitory effect on cell proliferation. This study aims to explore the inhibitory effect of propofol on lung metastasis of B16F10 melanoma in mice to provide a theoretical basis for propofol to be more suitable for surgical anaesthesia of malignant melanoma. Methods Cell viability was measured by CCK-8 assay. Flow cytometry was used to detect the apoptotic rate and Western blotting was used to detect the expression of DR5. In the in-vivo experiment, tumour cells were injected into the caudal vein to establish a lung metastatic model. Twenty-four male C57BL/6J mice were divided into 4 groups by random number table method, namely normal control group, melanoma lung metastasis model group, propofol 50 mg/kg, 10 mg/kg groups, 6 mice in each group. The effect of intraperitoneal injection of propofol on tumour metastatic nodules in the lung tissue of mice was observed. Results In the in-vitro experiment, the relative proliferation capacity (490 nm OD value) of cells in the control group and 10 μmol/L, 50 μmol/L, 100 μmol/L groups at 72 h were 0.91±0.03, 0.81±0.02, 0.71±0.02 and 0.61±0.02, respectively. The apoptotic rates of B16F10 cells treated with 100 μmol/L propofol were (8.09±1.01) %, (26.04±1.10) %, (32.94±1.30) % at 24, 48 and 72 h, respectively. In the in-vivo experiment, intraperitoneal injection of propofol at a dose of 50 mg/kg could significantly inhibit the number of nodules in lung metastatic melanoma and the immunohistochemical results showed that the expression of DR5 in lung tissue significantly increased in the propofol group. Conclusion Propofol could inhibit lung metastatic melanoma in mice and the mechanism may be related to the up-regulation of DR5 protein expression.
- Malignant Melanoma /
- Propofol /
- Death receptor 5 /
- Proliferation /
- Apoptosis

HTML全文

图 1 丙泊酚的化学结构式

Figure 1. The chemical formula for propofol

下载: 全尺寸图片幻灯片

图 2 丙泊酚对B16F10细胞增殖的影响

Figure 2. Effect of propofol on the proliferation of B16F10 cells

下载: 全尺寸图片幻灯片

图 3 100 μmol/L丙泊酚不同时间点对B16F10细胞凋亡的影响

Figure 3. Effects of 100 μmol/L propofol on apoptosis of B16F10 cells at different time points

下载: 全尺寸图片幻灯片

图 4 不同浓度丙泊酚作用72 h后对B16F10细胞DR5蛋白表达的影响

Figure 4. Effect of different concentrations of propofol on the expression of DR5 protein in B16F10 cells after 72 h

下载: 全尺寸图片幻灯片

图 5 丙泊酚对B16F10肺转移及DR5表达的影响

注：1为正常对照组；2为高剂量丙泊酚(50 mg/kg)给药组；3为低剂量丙泊酚(10 mg/kg)给药组；4为疾病模型组。

Figure 5. Effect of propofol on B16F10 lung metastasis and DR5 expression

下载: 全尺寸图片幻灯片

参考文献(23)

[1]	WALSH C T. Propofol: Milk of amnesia[J]. Cell, 2018, 175(1): 10-13. doi: 10.1016/j.cell.2018.08.031
[2]	HAUSBURG M A, BANTON K L, ROMAN P E, et al. Effects of propofol on ischemia-reperfusion and traumatic brain injury[J]. J Crit Care, 2020, 56: 281-287. doi: 10.1016/j.jcrc.2019.12.021
[3]	LIU J H, AI P, SUN Y Y, et al. Propofol inhibits microglial activation via miR-106b/Pi3k/Akt Axis[J]. Front Cell Neurosci, 2021, 15: 768364. DOI: 10.3389/fncel.2021.768364.
[4]	GAO X C, MI Y J, GUO N, et al. The mechanism of propofol in cancer development: An updated review[J]. Asia Pac J Clin Oncol, 2020, 16(2): e3-e11.
[5]	WANG J Q, CHENG C S, LU Y, et al. Novel findings of anti-cancer property of propofol[J]. Anticancer Agents Med Chem, 2018, 18(2): 156-165. doi: 10.2174/1871520617666170912120327
[6]	KAJIWARA M, KATO R, OI Y, et al. Propofol decreases spike firing frequency with an increase in spike synchronization in the cerebral cortex[J]. J Pharmacol Sci, 2020, 142(3): 83-92. doi: 10.1016/j.jphs.2019.11.005
[7]	AHMED B, QADIR M I, GHAFOOR S. Malignant melanoma: Skin cancer-diagnosis, prevention, and treatment[J]. Crit Rev Eukaryot Gene Expr, 2020, 30(4): 291-297. doi: 10.1615/CritRevEukaryotGeneExpr.2020028454
[8]	李旭文, 宋培军, 李薇, 等. miR-182增强黑色素瘤细胞增殖和侵袭的作用研究[J]. 中华全科医学, 2021, 19(9): 1474-1476, 1548. doi: 10.16766/j.cnki.issn.1674-4152.002089 LI X W, SONG P J, LI W, et al. MiR-182 enhances and promotes the proliferation and invasion of melanoma cells[J]. Chinese Journal of General Practice, 2021, 19(9): 1474-1476, 1548. doi: 10.16766/j.cnki.issn.1674-4152.002089
[9]	DE MIGUEL D, LEMKE J, ANEL A, et al. Onto better TRAILs for cancer treatment[J]. Cell Death Differ, 2016, 23(5): 733-747. doi: 10.1038/cdd.2015.174
[10]	KOJIMA Y, NISHINA T, NAKANO H, et al. Inhibition of Importin β1 augments the anticancer effect of agonistic anti-death receptor 5 antibody in TRAIL-resistant tumor cells[J]. Mol Cancer Ther, 2020, 19(5): 1123-1133. doi: 10.1158/1535-7163.MCT-19-0597
[11]	XU Y C, PAN S Y, JIANG W X, et al. Effects of propofol on the development of cancer in humans[J]. Cell Prolif, 2020, 53(8): e12867.
[12]	YAP A, LOPEZ-OLIVO M A, DUBOWITZ J, et al. Anesthetic technique and cancer outcomes: A meta-analysis of total intravenous versus volatile anesthesia[J]. Can J Anaesth, 2019, 66(5): 546-561. doi: 10.1007/s12630-019-01330-x
[13]	何永军, 金玮蔚, 方弘伟. 丙泊酚与七氟烷对单肺通气状态下胸科手术患者炎症因子和肺功能影响的对比分析[J]. 中华全科医学, 2018, 16(12): 2021-2023, 2031. doi: 10.16766/j.cnki.issn.1674-4152.000551 HE Y J, JIN W W, FANG H W. Comparative analysis of effects of propofol and sevoflurane on inflammatory factors and pulmonary function in patients undergoing thoracic surgery with one lung ventilation[J]. Chinese Journal of General Practice, 2018, 16(12): 2021-2023, 2031. doi: 10.16766/j.cnki.issn.1674-4152.000551
[14]	田诗意, 吴悠, 李远, 等. 丙泊酚抑制STAT3磷酸化对乳腺癌MCF-7细胞转移的影响[J]. 肿瘤, 2020, 40(8): 549-556. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL202008004.htm TIAN S Y, WU Y, LI Y, et al. Effect of propofol on metastasis of breast cancer MCF-7 cells by inhibiting phosphorylation of STAT3[J]. Tumor, 2020, 40(8): 549-556. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL202008004.htm
[15]	杨陈祎, 王海云, 王欣悦, 等. 丙泊酚对大鼠脑胶质瘤侵袭力的影响[J]. 中华麻醉学杂志, 2017, 37(11): 1342-1346. YANG C Y, WANG H Y, WANG X Y, et al. Effect of propofol on invasion of cerebral glioma in rats[J]. Chinese Journal of Anesthesiology, 2017, 37(11): 1342-1346.
[16]	孟星君, 李孝东, 刘俊, 等. C57BL/6 J小鼠黑色素瘤肺转移模型的构建[J]. 中国实验动物学报, 2018, 26(2): 139-144. doi: 10.3969/j.issn.1005-4847.2018.02.001 MENG X J, LI X D, LIU J, et al. Establishment of a C57BL/6 J mouse model of metastatic melanoma in the lung[J]. Acta Laboratorium Animalis Scientia Sinica, 2018, 26(2): 139-144. doi: 10.3969/j.issn.1005-4847.2018.02.001
[17]	ZHANG J, ZHOU Y, LI N, et al. Curcumol overcomes TRAIL resistance of non-small cell lung cancer by targeting NRH: Quinone Oxidoreductase 2 (NQO2)[J]. Adv Sci (Weinh), 2020, 7(22): 2002306. DOI: 10.1002/advs.202002306.
[18]	KIM B R, PARK S H, JEONG Y A, et al. RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer[J]. Oncogene, 2019, 38(20): 3903-3918. doi: 10.1038/s41388-019-0693-x
[19]	MIN K J, WOO S M, SHAHRIYAR S A, et al. Elucidation for modulation of death receptor (DR) 5 to strengthen apoptotic signals in cancer cells[J]. Arch Pharm Res, 2019, 42(1): 88-100. doi: 10.1007/s12272-018-01103-y
[20]	DENG D, SHAH K. TRAIL of hope meeting resistance in cancer[J]. Trends Cancer, 2020, 6(12): 989-1001. doi: 10.1016/j.trecan.2020.06.006
[21]	MONTICO B, NIGRO A, CASOLARO V, et al. Immunogenic apoptosis as a novel tool for anticancer vaccine development[J]. Int J Mol Sci, 2018, 19(2): 594. doi: 10.3390/ijms19020594
[22]	YUAN X, GAJAN A, CHU Q, et al. Developing TRAIL/TRAIL death receptor-based cancer therapies[J]. Cancer Metastasis Rev, 2018, 37(4): 733-748. doi: 10.1007/s10555-018-9728-y
[23]	VON KARSTEDT S, MONTINARO A, WALCZAK H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy[J]. Nat Rev Cancer, 2017, 17(6): 352-366. doi: 10.1038/nrc.2017.28